Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010)

References

• Marincola FM, Jaffee EM, Hicklin JD, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol.174, 181–273 (2000).
   Google Scholar
• Shiozaki A, Kataoka K, Fujimura M, Yuki H, Sakai M, Saito S. Survivin inhibits apoptosis in cytotrophoblasts. Placenta24(1), 65–76 (2003).
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Petrini M, Fiammenghi L, Riccobon A, Ridolfi R. Human embryo immune escape mechanisms rediscovered by the tumor. Immunobiology214(1), 61–76 (2009).
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol.90, 1–50 (2006).
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Smyth MJ et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med.7(1), 94–100 (2001).
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer4(1), 71–78 (2004).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol.6(11), 836–848 (2006).
   PubMed Web of Science ®Google Scholar
• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol.19(2), 203–208 (2007).
   PubMed Web of Science ®Google Scholar
• Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res.67(11), 5064–5066 (2007).
   PubMed Web of Science ®Google Scholar
• Street SE, Zerafa N, Iezzi M et al. Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res.67(11), 5454–5460 (2007).
   PubMed Web of Science ®Google Scholar
• Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev. Mol. Med.9(4), 1–20 (2007).
   PubMedGoogle Scholar
• Moschos S, Varanasi S, Kirkwood JM. Interferons in the treatment of solid tumors. Cancer Treat. Res.126, 207–241 (2005).
   PubMedGoogle Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol.14(1), 7–17 (1996).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon α-2b in high-risk melanoma:first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol.18(12), 2444–2458 (2000).
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon α-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol.24(19), 3164–3171 (2006).
   PubMed Web of Science ®Google Scholar
• Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat. Rev.33(8), 665–680 (2007).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat. Clin. Pract. Oncol.6(2), 70–71 (2009).
   PubMedGoogle Scholar
• Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin. Immunol.127(2), 123–129 (2008).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst. Rev.1, CD005413 (2007).
   Google Scholar
• Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J. Clin. Oncol.25(34), 5426–5434 (2007).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol.23(10), 2346–2357 (2005).
   PubMed Web of Science ®Google Scholar
• Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J. Invest. Dermatol.128(11), 2596–2605 (2008).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol.26(32), 5233–5239. (2008).
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol.23(4), 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Cutler CW, Jotwani R, Pulendran B. Dendritic cells: immune saviors or Achilles’ heel? Infect. Immun.69(8), 4703–4708 (2001).
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev.224, 141–165 (2008).
   PubMed Web of Science ®Google Scholar
• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol.90, 297–339 (2006).
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat. Rev. Immunol.2(2), 116–126 (2002).
   PubMed Web of Science ®Google Scholar
• Chen J, He Q, Zhang R et al. Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival. Clin. Exp. Immunol.138(2), 245–250 (2004).
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med.5(12), 1365–1369 (1999).
   PubMed Web of Science ®Google Scholar
• Tseng SY, Otsuji M, Gorski K et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med.193(7), 839–846 (2001).
   PubMed Web of Science ®Google Scholar
• Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol. Med.14(12), 550–559 (2008).
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily – CTLA-4. Nature328(6127), 267–270 (1987).
   PubMed Web of Science ®Google Scholar
• Dariavach P, Mattéi MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur. J. Immunol.18(12), 1901–1905 (1988).
   PubMed Web of Science ®Google Scholar
• Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity7(4), 445–450 (1997).
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity1(5), 405–413 (1994).
   PubMed Web of Science ®Google Scholar
• Kearney ER, Walunas TL, Karr RW et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol.155(3), 1032–1036 (1995).
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med.182(2), 459–465 (1995).
   PubMed Web of Science ®Google Scholar
• Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int. Immunol.8(4), 519–523 (1996).
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity3(5), 541–547 (1995).
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science270(5238), 985–988 (1995).
   PubMed Web of Science ®Google Scholar
• Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity7(6), 885–895 (1997).
   PubMed Web of Science ®Google Scholar
• Schneider H, Downey J, Smith Aet al. Reversal of the TCR stop signal by CTLA-4. Science313(5795), 1972–1975 (2006).
   PubMed Web of Science ®Google Scholar
• Downey J, Smith A, Schneider H, Hogg N, Rudd CE. TCR/CD3 mediated stop-signal is decoupled in T-cells from Ctla4 deficient mice. Immunol. Lett.115(1), 70–72 (2008).
   PubMed Web of Science ®Google Scholar
• Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res.13(6), 1810–1815 (2007).
   PubMed Web of Science ®Google Scholar
• Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr. Opin. Investig. Drugs6(6), 582–591 (2005).
   PubMedGoogle Scholar
• Melero I, Shuford WW, Newby SA et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med.3(6), 682–685 (1997).
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med.190(3), 355–366 (1999).
   PubMed Web of Science ®Google Scholar
• Keler T, Halk E, Vitale L et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol.171(11), 6251–6259 (2003).
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol.12(12), 1005–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Kavanagh B, O’Brien S, Lee D et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood112(4), 1175–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Maker AV, Yang JC, Sherry RM et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother.29(4), 455–463 (2006).
   PubMed Web of Science ®Google Scholar
• Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol.28(10), 3137–3143 (1998).
   PubMed Web of Science ®Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl Acad. Sci. USA103(24), 9190–9195 (2006).
   PubMed Web of Science ®Google Scholar
• Contardi E, Palmisano GL, Tazzari PL et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer117(4), 538–550 (2005).
   PubMed Web of Science ®Google Scholar
• Hoos A, Chasalow SD, Parker SM et al. Ipilimumab 10mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 785P).
   Google Scholar
• Davis TA, Tchekmedyian S, Korman A, Keler T, Deo Y, Small EJ. MDX-010 (human anti-CTLA4): a Phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc. Am. Soc. Clin. Oncol.21(Suppl.), (2002) (Abstract 74).
   Google Scholar
• Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis TA. MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma. Proc. Am. Soc. Clin. Oncol.21(Suppl.), (2002) (Abstract 56).
   Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA100(8), 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Weber JS, O’Day S, Urba W et al. Phase I/II Study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol.26(36), 5950–5956 (2008).
   PubMed Web of Science ®Google Scholar
• Weber JS, Hersh EM, Yellin M et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 8523).
   Google Scholar
• Lebbe C, Hoos A, Chin K et al. Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma-results from a Phase II, randomized, dose-ranging study. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 7690).
   Google Scholar
• Hamid O, Chin K, Li J et al. Dose effect of ipilimumab in patients with advanced melanoma: results from a Phase II, randomized, dose-ranging study. J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract 9025).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Ibrahim R, DePril V et al. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract 9021).
   PubMedGoogle Scholar
• Weber JS, Berman D, Siegel J et al. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract 9010).
   Web of Science ®Google Scholar
• Ron I, Berman D, Siegel J et al. Efficacy and safety of patients with advanced melanoma treated with ipilimumab with or without the addition of prophylactic budesonide. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 783P).
   Google Scholar
• Ridolfi R, Berman D, Siegel J et al. Efficacy and safety of treatment-naïve and previously treated patients with advanced melanoma receiving ipilimumab. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 778P).
   Google Scholar
• Maio M, Hoos A, Ibrahim R et al. Efficacy and safety of ipilimumab in patients with advanced melanoma who had progressed on one or more prior therapies: results from a single-arm, multicenter study. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 776PD).
   PubMedGoogle Scholar
• Hersh E M, Weber JS, Powderly JD et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract 9022).
   Google Scholar
• Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol.175(11), 7746–7754 (2005).
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23(25), 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr. Opin. Investig. Drugs.6(6), 582–591 (2005).
   PubMedGoogle Scholar
• Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol.18(2), 206–213 (2006).
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison J. Enhancement of antitumor immunity by CTLA-4 blockade. Science271(5256), 1734–1736 (1996).
   PubMed Web of Science ®Google Scholar
• Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl Acad. Sci. USA96(20), 11476–11481 (1999).
   PubMed Web of Science ®Google Scholar
• Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity11(4), 483–493 (1999).
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med.194(6), 823–832 (2001).
   PubMed Web of Science ®Google Scholar
• Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res.63(12), 3281–3288 (2003).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Fischkoff SA, Hersh E, Weber J et al. Durable responses and long-term progression-free survival observed in a Phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J. Clin. Oncol.23(16 Suppl.), (2005) (Abstract 7525).
   Google Scholar
• Reuben JM, Lee BN, Li C et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer106(11), 2437–2444 (2006).
   PubMed Web of Science ®Google Scholar
• Weber JS, Targan S, Scotland R et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected syages IIIc and IV melanoma. J. Clin. Oncol.24(18 Suppl.), (2006) (Abstract 2510).
   Google Scholar
• Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol.24(15), 2283–2289 (2006).
   PubMed Web of Science ®Google Scholar
• Antonia S, Sosman J, Kirkwood JM et al. Natural history of diarrhea associated with the anti-CTLA-4 monoclonal antibody. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 3038).
   Google Scholar
• Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother.28(6), 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Chin K, Ibrahim R, Berman D et al. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA-4 therapy. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 787P).
   Google Scholar
• Weber J. Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist12(7), 864–872 (2007).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer110(12), 2614–2627 (2007).
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res.13(22), 6681–6688 (2007).
   PubMed Web of Science ®Google Scholar
• Hamid O, Urba WJ, Yellin M et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 8525).
   Google Scholar
• Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol.26(32), 5275–5283 (2008).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Butler M, Oble DA et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA105(8), 3005–3010 (2008).
   PubMed Web of Science ®Google Scholar
• Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun.17(8), 1 (2008).
   Google Scholar
• Harmankaya K, Pehamberger H, Hoos A et al. Ipilimumab-mediated patterns of response in patients with pretreated, advanced melanoma. Ann. Oncol.19(8 Suppl.), (2008) (Abstract 784P).
   Google Scholar
• Tuma RS. New response criteria proposed for immunotherapies. J. Natl Cancer Inst.100(18), 1280–1281 (2008).
   PubMedGoogle Scholar
• Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist13(4 Suppl.), 16–25 (2008).
   PubMed Web of Science ®Google Scholar
• Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother.58(5), 823–830 (2009).
   PubMed Web of Science ®Google Scholar
• Keilholz U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J. Immunother.31(5), 431–439 (2008).
   PubMed Web of Science ®Google Scholar
• Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat. Anticancer Drug Discov.3(2), 105–113 (2008).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Tarhini AA, Panelli MC et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol.26(20), 3445–3455 (2008).
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer7(2), 95–106 (2007).
   PubMed Web of Science ®Google Scholar
• Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J. Immunother.31(6), 586–590 (2008).
   PubMed Web of Science ®Google Scholar